Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial

Publication date: Available online 2 September 2019Source: The LancetAuthor(s): Juan F Iglesias, Olivier Muller, Dik Heg, Marco Roffi, David J Kurz, Igal Moarof, Daniel Weilenmann, Christoph Kaiser, Maxime Tapponnier, Stefan Stortecky, Sylvain Losdat, Eric Eeckhout, Marco Valgimigli, Ayodele Odutayo, Marcel Zwahlen, Peter Jüni, Stephan Windecker, Thomas PilgrimSummaryBackgroundNewer-generation drug-eluting stents that combine ultrathin strut metallic platforms with biodegradable polymers might facilitate vascular healing and improve clinical outcomes in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention (PCI) compared with contemporary thin strut second-generation drug-eluting stents. We did a randomised clinical trial to investigate the safety and efficacy of ultrathin strut biodegradable polymer sirolimus-eluting stents versus thin strut durable polymer everolimus-eluting stents in patients with acute ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI.MethodsThe BIOSTEMI trial was an investigator-initiated, multicentre, prospective, single-blind, randomised superiority trial at ten hospitals in Switzerland. Patients aged 18 years or older with acute STEMI who were referred for primary PCI were eligible to participate. Patients were randomly allocated (1:1) to either biodegradable polymer sirolimus-eluting stents or durable polymer everolimus-eluting stents. Central randomisation was done based on a compute...
Source: The Lancet - Category: General Medicine Source Type: research